![ATAGI statement on use of the Moderna bivalent Original/Omicron vaccine | Australian Government Department of Health and Aged Care ATAGI statement on use of the Moderna bivalent Original/Omicron vaccine | Australian Government Department of Health and Aged Care](https://www.health.gov.au/sites/default/files/styles/h_content_max_width_no_upscale/public/images/news/2022/09/atagi-statement-on-use-of-the-moderna-bivalent-original-omicron-vaccine.png?itok=BIYw_3RB)
ATAGI statement on use of the Moderna bivalent Original/Omicron vaccine | Australian Government Department of Health and Aged Care
![Omicron Subvariant Now Dominant in U.S.; FDA, CDC OK Second Booster for Adults Over 50 | The Hospital of Central Connecticut | CT Omicron Subvariant Now Dominant in U.S.; FDA, CDC OK Second Booster for Adults Over 50 | The Hospital of Central Connecticut | CT](https://healthnewshub.org/wp-content/uploads/2022/03/Newsba2OmicronCovid.jpg)
Omicron Subvariant Now Dominant in U.S.; FDA, CDC OK Second Booster for Adults Over 50 | The Hospital of Central Connecticut | CT
![Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 | MMWR Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/figures/mm7118a4-F-large.gif?_=74292)
Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022 | MMWR
![Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-01832-0/MediaObjects/41591_2022_1832_Fig1_HTML.png)
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine
![Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design - The Lancet Infectious Diseases Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/91d19b8e-2f0b-4e13-8d9b-69e012d37e25/gr1.jpg)
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design - The Lancet Infectious Diseases
![Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7148e1-BivalentBooster_IMAGE_22NOV2022_1200x675.jpg?_=65732)
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR
![Quarta dose contro Covid-19: perché, a chi, quando e con quale vaccino - Network Bibliotecario Sanitario Toscano Quarta dose contro Covid-19: perché, a chi, quando e con quale vaccino - Network Bibliotecario Sanitario Toscano](https://www.mdpi.com/vaccines/vaccines-10-01924/article_deploy/html/images/vaccines-10-01924-g001.png)
Quarta dose contro Covid-19: perché, a chi, quando e con quale vaccino - Network Bibliotecario Sanitario Toscano
![Second Pfizer/BioNTech bivalent COVID-19 booster vaccine approved by UK medicines regulator - GOV.UK Second Pfizer/BioNTech bivalent COVID-19 booster vaccine approved by UK medicines regulator - GOV.UK](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/image_data/file/166637/s960_Gov_UK.jpg)
Second Pfizer/BioNTech bivalent COVID-19 booster vaccine approved by UK medicines regulator - GOV.UK
![Vaccines | Free Full-Text | COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects Vaccines | Free Full-Text | COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects](https://pub.mdpi-res.com/vaccines/vaccines-10-01223/article_deploy/html/images/vaccines-10-01223-g001-550.jpg?1659772982)